Patents Represented by Attorney Todd Lorenz
  • Patent number: 7812124
    Abstract: A method of diagnosing cancer comprising the identification of neoplastic molecular markers is disclosed. Tumor-related or neoplastic molecular markers are identified from samples taken from a subject and the molecular profile of those markers is determined. Based upon the neoplastic molecular marker profile of the subject, the tumor sub-type is ascertained and an appropriate treatment protocols initiated.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: October 12, 2010
    Inventor: Kaia Palm
  • Patent number: 7671026
    Abstract: The methods and compositions relate to treatment of disorders of the bladder. In particular, the methods provide for treatment of interstitial cystitis and related disorders. The methods further comprise treatment to affect various manifestations associated with interstitial cystitis, including, reducing histamine release, modulating Substance P expression, modulating nerve growth factor expression, modulating levels of various cytokines, and maintaining integrity of the urine/blood barrier.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: March 2, 2010
    Assignee: Sangstat Medical Corporation
    Inventors: Timothy Fong, Alexis E. Te
  • Patent number: 6696545
    Abstract: Novel oligopeptides comprising a sequence derived by a computer program are provided for use in inhibiting cytotoxic activity of lymphocytic cells, inhibiting the production of inflammatory cytokines and inflammatory responses associated with those cytokines, inhibiting the activity of heme-containing enzymes and delaying the onset of an autoimmune disease in a mammal at risk of developing the disease. By combining the subject compositions with mixtures of cells comprising lymphocytic cells and cells which would otherwise activate the lymphocytic cells, lysis of the target cells can be substantially inhibited. The oligopeptides may be joined to a wide variety of other groups or compounds for varying the activity of the subject compositions.
    Type: Grant
    Filed: February 23, 1998
    Date of Patent: February 24, 2004
    Assignee: Sangstat Medical Corporation
    Inventors: Roland Buelow, Gèrard Grassy, Bernard Calas
  • Patent number: 6590091
    Abstract: Methods and compositions are provided for detecting nucleic acid sequences. In particular, pairs of probes are employed, where the pair defines a substantially contiguous sequence on a target nucleic acid. Each of the pairs has a side chain which forms a stem of the two side chains which non-covalently binds and is capable of forming a cross-link upon activation, when the probes and sample nucleic acid are base paired. Cross-linking of the stems when unbound to complementary DNA is inhibited. Each of the nucleic acids is initially present as single stranded nucleic acid to allow for base pairing, so that the probes bind to homologous target nucleic acid. The assay mixture is activated to provide cross-linking, the double stranded nucleic acid melted, and the process of base pairing, activation and melting repeated, a sufficient number of cycles, to provide a detectable amount of cross-linked probes.
    Type: Grant
    Filed: January 9, 2001
    Date of Patent: July 8, 2003
    Assignee: Naxcor
    Inventors: David Albagli, Reuel VanAtta, Michael Wood
  • Patent number: 6503747
    Abstract: Recombinant nucleic acids comprising region(s) of Listeria monocytogenes genome that are unique to an individual serotype and genomic cluster are provided. Also provided are oligonucleotide probes and primers derived from the recombinant nucleic acid sequences and methods for their use in the detection and identification serovar 4 and genomic cluster IIB strains.
    Type: Grant
    Filed: July 14, 1998
    Date of Patent: January 7, 2003
    Assignee: University of Hawaii
    Inventors: Sophia Kathariou, Xiang-He Lei
  • Patent number: 6495676
    Abstract: Methods and compositions are provided for detecting nucleic acid sequences. Probes comprising a crosslinking agent are combined with a sample which may comprise a target sequence which is complementary to the probe. Hybridization is allowed to occur between complementary sequences. The crosslinking agent is activated. Covalent bonds are formed between the probe and the target sequence if they are hybridized to one another. The crosslinked nucleic acids can then be detected to indicate the presence of the target sequence. Also provided are kits comprising reagents.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: December 17, 2002
    Assignee: Naxcor
    Inventors: Michael L. Wood, David Albagli, Reuel B. Van Atta, Douglas Y. Thien, Peter C. Cheng, Bingfang Huan
  • Patent number: 6420523
    Abstract: The present invention provides compositions of matter comprising a polypeptide expressed from insect cells harboring a baculovirus vector the encodes the polypeptide, wherein the polypeptide comprises amino acid sequences derived from the p42 fragment of the Plasmodium falciparum gp 195 protein or derivatives thereof. Such compositions of matter find use for example for inducing the production of anti-p42 antibodies both in vivo and in vitro.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: July 16, 2002
    Assignee: University of Hawaii
    Inventors: Sandra Chang, George S. N. Hui, Philip J. Barr, Helen Gibson
  • Patent number: 6403302
    Abstract: Improved oligonucleotides and processes for their use for specific recognition of a target sequence in double-stranded nucleic acid through the formation of an alternate strand triple-helix. The triple-helix forming oligonucleotides bind in a parallel and antiparallel orientation, respectively, to target sequences on alternate strands of the double helical nucleic acid. The oligonucleotides are useful as diagnostic or therapeutic agents and can incorporate an appropriate moiety in one or more nucleotides in the triple-helix forming oligonucleotide.
    Type: Grant
    Filed: December 16, 1993
    Date of Patent: June 11, 2002
    Assignee: California Institute of Technology
    Inventors: Peter B. Dervan, Peter A. Beal
  • Patent number: 6369116
    Abstract: Implants and methods are provided for modulating wound healing and controlling infection to improve the success of glaucoma filtration surgery. Formulations of one or more therapeutically active agents and a biodegradable polymer provide a substantially constant rate of release for an extended period of time.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: April 9, 2002
    Assignee: Oculex Pharmaceuticals, Inc.
    Inventors: Vernon Wong, Lin Peng
  • Patent number: 6350731
    Abstract: Novel peptide analogues of platelet-derived growth factor, for use in inhibiting or stimulating growth and/or chemotaxis of cells, for example, smooth muscle cells, are provided. Also provided are compositions of matter comprising those peptide analogues.
    Type: Grant
    Filed: November 2, 1999
    Date of Patent: February 26, 2002
    Assignee: Trigen Limited
    Inventors: Ahmed Mohammed Taki Jehanli, Geeta Patel, Yemisi Olabiran, David Mark Brennand, Vir Vijay Kakkar
  • Patent number: 6303317
    Abstract: Methods for creating and using polypeptide probes with high affinity for any desirable coiled coil region are described, as well as heterospecific polypeptide probes directed to the coiled coil region of a target polypeptide. Core residue packing rules are provided for selective amino acid pairing and packing in the hydrophobic core of the interhelical interface.
    Type: Grant
    Filed: January 28, 1998
    Date of Patent: October 16, 2001
    Assignee: The Regents of the University of California
    Inventors: Thomas C. Alber, Victoria Allen, Shivani Nautiyal
  • Patent number: 6277570
    Abstract: Methods and compositions are provided for detecting nucleic acid sequences. Probes comprising a crosslinking agent are combined with a sample which may comprise a target sequence which is complementary to the probe. Hybridization is allowed to occur between complementary sequences. The crosslinking agent is activated. Covalent bonds are formed between the probe and the target sequence if they are hybridized to one another. The crosslinked nucleic acids can then be detected to indicate the presence of the target sequence. Also provided are kits comprising reagents.
    Type: Grant
    Filed: September 4, 1998
    Date of Patent: August 21, 2001
    Assignee: Naxcor
    Inventors: Michael L. Wood, David Albagli, Reuel B. Van Atta, Peter C. Cheng, Bingfang Huan, Douglas Y. Thien
  • Patent number: 6207159
    Abstract: Methods for detecting the status of an insulin-dependent diabetes mellitus (IDDM)-associated autoimmune response in a mammal are provided. Specifically, the ratio of the frequency of T helper 1 cells to T helper 2 cells specific for a pancreatic &bgr;-cell associated antigen is indicative of the status of the autoimmune response. The methods may be employed prior to the onset of the clinical symptoms of the disease, thereby allowing identification of those at risk for developing clinical symptoms of IDDM, or subsequent to pancreatic tissue transplantation, for example, to measure the efficacy of treatment directed to enhancing the lifetime of the tissue transplant. Methods for prolonging the survival of tissue transplants are also provided. Specifically, a tissue-associated antigen is administered to the mammal which serves to shift the pathogenic Th1 response associated with pathological immunity toward a protective Th2 response.
    Type: Grant
    Filed: July 21, 1998
    Date of Patent: March 27, 2001
    Assignee: The Regents of the University of California
    Inventors: Daniel L. Kaufman, Jide Tian